Does injectable treatment mean surgery is off the table?

Being told you may need surgery for a cartilage problem does not automatically mean that surgery is the right starting point. For many patients with a focal cartilage defect in a mechanically stable joint, an ultrasound-guided ChondroFiller® collagen scaffold injection is now a clinically supported first choice — not a consolation prize for those who cannot face an operation.

This matters because it reorders the conversation. Previously, a patient with a significant chondral lesion was typically steered toward keyhole surgery — microfracture or a staged cell-based procedure — with injection therapies reserved for those deemed unsuitable for the operating theatre. The availability of an injectable scaffold that gels in situ and recruits the patient's own cells changes that logic: injection can be the primary pathway, and surgery the escalation if defect size or complexity genuinely demands it.

Not every cartilage problem suits the injection route. Defects that are too large, too complex, or combined with insufficient regenerative biology may still require a surgical procedure. The distinction turns on clinical fit, and that is what the sections below work through.

Why cartilage cannot repair itself

Unlike muscle, bone, or skin, articular cartilage has no blood vessels running through it, no nerve fibres, and no lymphatic channels. Those three systems are what normally allow the body to detect damage, recruit repair cells, and clear away injured tissue. Without them, cartilage has no reliable mechanism for healing itself — even a small focal defect from a sporting injury or accumulated wear is essentially invisible to the body's standard repair machinery.

The clinical consequence is straightforward: untreated focal defects tend not to stabilise on their own, and many enlarge progressively under load. Because the tissue cannot summon the biological environment it needs from within, any effective treatment — whether an injection or a surgical procedure — has to supply that environment from the outside. The question of which route does that most appropriately for a given patient is what separates an injection pathway from a cartilage operation.

How ChondroFiller works as an injectable collagen scaffold

ChondroFiller® is supplied as a liquid type I collagen solution and delivered under ultrasound guidance directly into the defect area during an outpatient appointment. Within three to five minutes of placement, the collagen gels in situ, conforming to the defect and forming a porous three-dimensional scaffold.

The scaffold itself contains no donor cells — it is entirely acellular. What it provides is a structural framework that signals to the patient's own progenitor cells, drawing them in from the surrounding synovium and subchondral bone. Once resident within the scaffold, those cells begin laying down extracellular matrix. This process — acellular matrix-induced chondrogenesis — supports the body's own repair processes rather than replacing them with laboratory-grown tissue or surgically provoked bleeding.

Microfracture drills through the subchondral bone to provoke a bleed from the marrow; the resulting clot organises into fibrocartilage, which is mechanically weaker than hyaline cartilage and in published series shows declining clinical results after two to three years. MACI — matrix-induced autologous chondrocyte implantation — requires a preliminary arthroscopy to harvest cartilage cells, a laboratory culture stage of several weeks, and a second surgical procedure to implant the seeded membrane.

ChondroFiller involves neither bone penetration nor cell harvesting. That is why the procedure is viable as a single outpatient appointment rather than a theatre case, and why it preserves all future treatment options, including escalation to a surgical approach should defect complexity ultimately demand it.

When injection is sufficient and when surgery is still needed

Knowing how the scaffold works is only part of the decision. The more pressing question for most patients is whether their particular presentation sits within the window that an injection can realistically address.

The injectable indication

ChondroFiller injection is suited to focal, post-traumatic cartilage defects in mechanically stable joints. There is no published upper age limit and no fixed ceiling on defect size for the injectable pathway — the scaffold is delivered across the full articular surface in a single outpatient appointment, making it appropriate for a wider range of presentations than procedures targeting one precisely bounded lesion.

When surgery is the right call

When a defect is too large or structurally complex for a scaffold injection alone, the preferred route shifts to Liquid Cartilage™ keyhole surgery, which pairs the collagen scaffold with mesenchymal stem cell co-delivery under direct arthroscopic visualisation. That combination provides the regenerative input and surgical precision that injection alone cannot reliably supply for more demanding defects.

Who falls outside the treatment window

Diffuse cartilage loss — generalised bone-on-bone degeneration spread across a joint surface rather than a localised defect — sits outside the ChondroFiller indication regardless of delivery route. In the hip, patients with pre-existing Tönnis grade 2 or 3 osteoarthritis consistently showed poor outcomes in a prospective cohort of 26 patients followed for up to five years (Mazek et al., 2021). Mechanical joint instability is a separate contraindication: an unstable loading environment compromises any scaffold repair before it can mature.

What the preference data add to the framework

Even among patients who are clinically eligible for surgery, the choice between pathways is rarely neutral. In a 2016 randomised multicentre study, six of the ten patients allocated to microfracture declined to proceed with the operation. That refusal rate is genuinely informative rather than incidental noise: it reflects a recurring pattern that consultants now incorporate into shared decision-making. When imaging supports a stand-alone injection and a patient leans away from surgical intervention, the clinical decision rule supports that preference — surgery in that setting represents over-treatment, not a default next step. The preference signal does not override clinical assessment; it becomes part of it.

What the evidence shows at 12–60 months

Across published knee series, patients tracked at 12 to 36 months show approximately 30-point improvements in IKDC scores — a validated functional measure where that magnitude represents a clinically meaningful shift in everyday activity. MRI assessment using the MOCART scale returns values of 70 to 87 in these cohorts, consistent with hyaline-like repair tissue rather than the mechanically weaker fibrocartilage associated with microfracture.

The hip cohort (Mazek et al., 2021, n=26) extends the follow-up window to five years. Of 21 evaluable patients, 17 achieved good or excellent results — noteworthy given that most cartilage-repair procedures lack published data beyond two years. Those outcomes align with the patient-selection criteria already described; the subset with pre-existing advanced joint degeneration is appropriately excluded before treatment begins.

For small-joint applications, Demmer et al. (2025) examined wrist cartilage at follow-up arthroscopy in 25 treated patients against 7 controls. Median Outerbridge scores were 1.5 versus 3 (P=0.006) and ICRS grading 1 versus 3 (P=0.002) in favour of the treated group. Fibrous tissue formed only in overfilled defects; flush applications were consistently free of it.

One safety-relevant finding warrants plain acknowledgement. A 2024 in-vitro biomechanical study found that ChondroFiller, in its early post-application state, did not reduce stress on the opposing cartilage surface during loading. That is the direct mechanical rationale for the standard six-week period of restricted weight-bearing: the scaffold requires time to stabilise before the joint returns to full load, and that protocol is the clinical response to the limitation rather than a workaround for it.

The evidence base is encouraging but maturing. Published data derive predominantly from small prospective cohorts and one underpowered randomised controlled trial; large head-to-head comparisons against MACI or microfracture with follow-up beyond five years have not yet been published.

Assessing your options at MSK Doctors

The net clinical takeaway from the preceding evidence is this: injectable collagen scaffold treatment has earned a genuine first-line role for focal, mechanically stable defects, but surgery has not been retired — it has been reserved for the cases that genuinely require it. That distinction, rather than a blanket preference for either pathway, is what a thorough imaging review exists to establish.

ChondroFiller® is a CE-marked Class III medical device; it is not currently NHS-funded and is available on a self-pay basis. At MSK Doctors, consultant-led assessments are offered at Sleaford, Lincolnshire (NG34) and Grantham (NG31) without a GP referral or NHS waiting list. Before any treatment decision is made, MRI review is required — the imaging determines whether the injectable pathway is appropriate, whether surgical referral is the better step, or whether further investigation is needed.

To arrange an assessment, appointments can be booked online at mskdoctors.com without a referral.

1. [1] Controlled, randomized multicenter study: ChondroFiller liquid vs microfracturing for focal cartilage defects of the knee. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
2. [2] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
3. [3] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y